DE69636720D1 - Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung - Google Patents

Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung

Info

Publication number
DE69636720D1
DE69636720D1 DE69636720T DE69636720T DE69636720D1 DE 69636720 D1 DE69636720 D1 DE 69636720D1 DE 69636720 T DE69636720 T DE 69636720T DE 69636720 T DE69636720 T DE 69636720T DE 69636720 D1 DE69636720 D1 DE 69636720D1
Authority
DE
Germany
Prior art keywords
fhf
factor
fibroblasted
methods
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636720T
Other languages
English (en)
Other versions
DE69636720T2 (de
Inventor
Jeremy Nathans
M Smallwood
P Macke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69636720D1 publication Critical patent/DE69636720D1/de
Publication of DE69636720T2 publication Critical patent/DE69636720T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69636720T 1995-05-12 1996-05-10 Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung Expired - Fee Related DE69636720T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US439725 1995-05-12
US08/439,725 US5693775A (en) 1995-05-12 1995-05-12 Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
PCT/US1996/006664 WO1996035708A1 (en) 1995-05-12 1996-05-10 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use

Publications (2)

Publication Number Publication Date
DE69636720D1 true DE69636720D1 (de) 2007-01-04
DE69636720T2 DE69636720T2 (de) 2007-10-18

Family

ID=23745874

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636720T Expired - Fee Related DE69636720T2 (de) 1995-05-12 1996-05-10 Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung

Country Status (8)

Country Link
US (4) US5693775A (de)
EP (2) EP1626096A3 (de)
JP (1) JPH11508125A (de)
AT (1) ATE346083T1 (de)
AU (1) AU718718B2 (de)
CA (1) CA2220893A1 (de)
DE (1) DE69636720T2 (de)
WO (1) WO1996035708A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019824A1 (en) * 1994-03-08 2005-01-27 Human Genome Sciences, Inc. Fibroblast Growth Factor-10
US6110893A (en) * 1995-06-05 2000-08-29 Human Genome Sciences, Inc. Fibroblast growth factor 11
EP0832216A4 (de) * 1995-06-05 1999-06-16 Human Genome Sciences Inc Fibroblaster wachstumsfaktor
US6605441B1 (en) 1995-06-05 2003-08-12 Human Genome Sciences, Inc. Antibodies against fibroblast growth factor 11
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
WO1996039420A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human criptin growth factor
US6020189A (en) 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
WO1998023749A1 (en) * 1996-11-27 1998-06-04 Human Genome Sciences, Inc. Fibroblast growth factor-13
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US7018810B1 (en) * 1999-12-07 2006-03-28 Amgen Inc. Chordin-like molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US7223563B2 (en) * 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US7776825B1 (en) * 2006-11-09 2010-08-17 Florida State University Research Foundation, Incorporated Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) * 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
EP2357020B1 (de) * 2010-02-17 2012-08-29 Sorin CRM SAS Aktive medizinische Vorrichtung vom Typ Herzschrittmacher, Defibrillator und/oder Resynchronisator mit automatischer Optimierung der atrioventrikulären Verzögerung
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2015061351A1 (en) * 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
KR101868620B1 (ko) * 2015-08-12 2018-07-23 중앙대학교 산학협력단 Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703979B1 (de) * 1993-06-04 2000-09-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5817485A (en) * 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
AU712297B2 (en) * 1995-06-05 1999-11-04 Human Genome Sciences, Inc. Fibroblast growth factor 11
EP0832216A4 (de) * 1995-06-05 1999-06-16 Human Genome Sciences Inc Fibroblaster wachstumsfaktor
CA2249179A1 (en) * 1996-03-21 1997-09-25 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use

Also Published As

Publication number Publication date
CA2220893A1 (en) 1996-11-14
DE69636720T2 (de) 2007-10-18
US5872226A (en) 1999-02-16
AU5739796A (en) 1996-11-29
EP1626096A3 (de) 2007-04-11
EP1626096A2 (de) 2006-02-15
AU718718B2 (en) 2000-04-20
EP0825996A1 (de) 1998-03-04
EP0825996B1 (de) 2006-11-22
US20030220483A1 (en) 2003-11-27
EP0825996A4 (de) 2000-06-14
US5693775A (en) 1997-12-02
US20020052477A1 (en) 2002-05-02
ATE346083T1 (de) 2006-12-15
JPH11508125A (ja) 1999-07-21
WO1996035708A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
AU735355C (en) Novel protein and method for producing the protein
IS4884A (is) Ret bindill til örvunar vaxtar tauga og thvagfæra
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
DK0745124T3 (da) Pattedyr-cellecyklusprotein
ATE83801T1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
DK564989A (da) Bindingsproteiner
ATE235916T1 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
DE69418322D1 (de) Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen
ATE216723T1 (de) Hormones de croissance humaines mutantes et leur utilisation
EP0967283A4 (de) Gene, die für proteine mit transglykolysierungsaktivität kodieren.
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
DE3854420D1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
EP0832109A4 (de) Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
DK0941341T3 (da) Nukleotidsekvens, der koder for en flavinmonooxygenase, det tilsvarende protein og deres anvendelser inden for diagnostik og terapi
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DE50311090D1 (de) Repressor der skelettmuskeldifferenzierung, dafür kodierende nucleinsäure und dessen verwendung in diagnostik und therapie
ATE110385T1 (de) Derivate von aminocarboxylsäure.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee